Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
暂无分享,去创建一个
Kimberly Smith | H. Crauwels | E. Overton | V. van Eygen | W. Spreen | H. Jaeger | D. Margolis | G. Rizzardini | R. Mngqibisa | J. Andrade-Villanueva | F. Ajana | S. Ford | P. Benn | C. Talarico | R. van Solingen-Ristea | A. Thalme | S. Vanveggel | G. Richmond | Yuanyuan Wang | Krischan J. Hudson | E. Belonosova | Antonio Ocampo Hermida | C. M. Español